Surgical robotics is no longer a monopoly: Intuitive's da Vinci remains the scaled, cash-generative incumbent, but Medtronic, J&J, Stryker and a wave of FDA-cleared challengers have turned soft-tissue and orthopedic robotics into a genuinely competitive, still-compounding hospital-capex category.
📈 What changed: 2026-07-20: Roster fix — Asensus Surgical (ASXC) removed from companies/tickers after its August 2024 acquisition by KARL STORZ (private) closed and ASXC ceased trading on NYSE Am…
| Indicator | Score | Reading |
|---|---|---|
| Maturity higher is better · high confidence | 82/100 | Scaled, commodity-grade incumbent (da Vinci) now facing genuine multi-vendor competition across specialties. |
| Evidence Strength higher is better · high confidence | 69/100 | Corroborated by SEC filings and FDA clearance records; independent economic-benefit literature is thinner than the adoption data. |
| Commercial Proximity higher is better · high confidence | 78/100 | Recurring, at-scale hospital revenue today; the near-term wedge is proven, not aspirational. |
| Capital & Policy Support higher is better · high confidence | 31/100 | Reimbursement-code and FDA-clearance driven, not publicly subsidised; no coordinated national strategy exists for surgical robotics specifically. |
| Crowding Risk lower is better · medium confidence | 78/100 | The incumbent trades at a rich, heavily-covered premium; challenger names are smaller and less crowded. |
| Reflexivity Risk lower is better · high confidence | 15/100 | Earnings-grounded and cash-generative at the core; challenger names carry more capital-markets dependence. |
Every indicator score is computed by the Northstar engine from analyst-set ordinal bands — never hand-written, never stored.
The public page is the summary (backed by 8 cited sources). Full briefing — company map, catalysts, native signals and sources — is inside the app.
Open in the appStart free →The Northstar Signal — what moved across all 350 themes and why, in your inbox. Free, no spam, one-click unsubscribe.